Pheochromocytoma:Rediscovery as a Catecholamine-Metabolizing Tumor

Endocrine Pathology

Volumn 14, Issue 3, 2003, Pages 193-212

  Eisenhofer, Graeme ^a   Goldstein, David S ^a   Kopin, Irwin J ^a   Crout, J Richard ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Adrenal glands; Catecholamines; Chromaffin cells; Epinephrine; Hypertension; Metabolism; Metanephrine; Norepinephrine; Normetanephrine; Paraganglioma; Pheochromocytoma; Secretion; Synthesis

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; CLONIDINE; DOPAMINE; METADRENALIN; NORADRENALIN; NORMETADRENALIN; SULFOTRANSFERASE; VANILMANDELIC ACID;

ADRENAL GLAND; BLOOD LEVEL; CATECHOLAMINE METABOLISM; CATECHOLAMINE RELEASE; CATECHOLAMINE SYNTHESIS; CHROMAFFIN CELL; HUMAN; HYPERTENSION; NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PLASMA; PRIORITY JOURNAL; REVIEW; URINALYSIS;

ADRENAL GLAND NEOPLASMS; CATECHOLAMINES; HUMANS; METANEPHRINE; METHYLATION; ORGAN SPECIFICITY; PHEOCHROMOCYTOMA; SULFATES;

EID: 0242288596     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:14:3:193     Document Type: Review

References (92)

1. Blaschko H, Richter D, Schlossmann H. The inactivation of adrenaline. J Physiol 90:1-17, 1937.
2. Richter D. The inactivation of adrenaline in vivo in man. J Physiol 98:361-373, 1940.
3. Armstrong MD, McMillan A. 3-Methoxy-4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine. Biochim Biophys Acta 25:422-423, 1957.
4. Armstrong MD, McMillan A. Studies on the formation of 3-methoxy-4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine and epinephrine. Pharmacol Rev 11: 394-401, 1958.
5. Gitlow SE, Mendlowitz M, Khassis S, Cohen G, Sha J. Diagnosis of pheochromocytoma by determination of urinary 3-methoxy-4-hydroxymandelic acid. J Clin Invest 39:221-226, 1960.
6. Goldenberg M, Serlin I, Edwards T, Rappaport MM. Chemical screening methods for the diagnosis of pheochromocytoma. Am J Med 16:310-327, 1954.
7. Axelrod J. O-Methylation of epinephrine and other catechols in vitro and in vivo. Science 126:400-401, 1957.
8. Landsberg L, Young JB. Physiology and pharmacology of the autonomic nervous system. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine, 15 ed. McGraw-Hill, New York, pp. 439-443, 2001.
9. Cryer PE. Diseases of the sympathochromaffin system. In: Felig P, Frohman LA, eds. Endocrinology and metabolism, 4 ed. McGraw-Hill, New York, pp 525-551, 2001.
10. Atlas SA. Endocrine hypertension. In: Massry SG, Glassock RJ, eds. Massry & Glassock's textbook of nephrology, 3 ed. Lippincott Williams & Williams, Philadelphia, pp. 1169-1183, 2001.
11. Bouloux P-MG. The sympatho-adrenal system, phaeochromocytoma and related tumors. In: Grossman A, ed. Clinical endocrinology, 2 ed. Blackwell Science, Oxford, pp. 497-520, 1998.
12. O'Connor DT. The adrenal medulla, catecholamines, and pheochromocytoma. In: Goldman L, Bennet JC, eds. The adrenal medulla, catecholamines, and pheochromocytoma, 21 ed. Saunders, Philadelphia, pp. 1257-1262, 2000.
13. Bravo EL. The adrenal medulla: basic concepts. In: Pinchera A, Bertagna XY, Fischer JA, Groop L, Schoemaker J, Serio M, Wass JAH, Braverman LE, eds. Endocrinology and metabolism. McGraw-Hill International (UK) Ltd, London, pp. 337-339, 2001.
14. Lenz T, Gossmann J, Schulte KL, Salewski L, Geiger H. Diagnosis of pheochromocytoma. Clin Lab 48:5-18, 2002.
15. 3H-3-methoxy-4-hydroxymandelic acid. J Clin Endocrinol Metab 30:580-589, 1970.
16. Blombery PA, Kopin IJ, Gordon EK, Markey SP, Ebert MH. Conversion of MHPG to vanillylmandelic acid. Implications for the importance of urinary MHPG. Arch Gen Psychiatry 37:1095-1098, 1980.
17. Mårdh G, Sjoquist B, Anggard E. Norepinephrine metabolism in man using deuterium labelling: the conversion of 4-hydroxy-3-methoxyphenylglycol to 4-hydroxy-3-methoxymandelic acid. J Neurochem 36:1181-1185, 1981.
18. Mårdh G, Änggård E. Norepinephrine metabolism in man using deuterium labelling: origin of 4-hydroxy-3-methoxymandelic acid. J Neurochem 42:43-46, 1984.
19. Mårdh G, Luehr CA, Vallee BL. Human class I alcohol dehydrogenases catalyze the oxidation of glycols in the metabolism of norepinephrine. Proc Natl Acad Sci USA 82: 4979-4982, 1985.
20. Eisenhofer G, Aneman A, Hooper D, Holmes C, Goldstein DS, Friberg P. Production and metabolism of dopamine and norepinephrine in mesenteric organs and liver of swine. Am J Physiol 268:G641-649, 1995.
21. Eisenhofer G, Aneman A, Hooper D, Rundqvist B, Friberg P. Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. J Neurochem 66:1565-1573, 1996.
22. Eriksson BM, Persson BA. Liquid chromatographic method for the determination of 3,4-dihydroxyphenylethylene glycol and 3,4-dihydroxymandelic acid in plasma. J Chromatogr 386:1-9, 1987.
23. Eisenhofer G, Goldstein DS, Stull R, Ropchak TG, Keiser HR, Kopin IJ. Dihydroxyphenylglycol and dihydroxymandelic acid during intravenous infusions of noradrenaline. Clin Sci (Lond) 73:123-125, 1987.
24. Kawamura M, Kopin IJ, Kador PF, Sato S, Tjurmina O, Eisenhofer G. Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. J Auton Nerv Syst 66:145-148, 1997.
25. Breese GR, Chase TN, Kopin IJ. Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain. J Pharmacol Exp Ther 165:9-13, 1969.
26. Tabakoff B, Anderson R, Alivisatos SG. Enzymatic reduction of "biogenic" aldehydes in brain. Mol Pharmacol 9:428-437, 1973.
27. Kawamura M, Eisenhofer G, Kopin IJ, et al. Aldose reductase: an aldehyde scavenging enzyme in the intraneuronal metabolism of norepinephrine in human sympathetic ganglia. Auton Neurosci 96:131-139, 2002.
28. Kopin IJ. Storage and metabolism of catecholamines: the role of monoamine oxidase. Pharmacol Rev 16:179-191, 1964.
29. Maas JW, Benensohn H, Landis DH. A kinetic study of the disposition of circulating norepinephrine in normal male subjects. J Pharmacol Exp Ther 174:381-387, 1970.
30. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667-1676, 1996.
31. Axelrod J, LaBrosse EH, Kety SS. O-Methylation, the principal route of metabolism of epinephrine in man. Science 128:593-594, 1958.
32. 3H-epinephrine-D-bitartrate in normal young men. J Clin Invest 40:253-260, 1961.
33. 3H released by tyramine and reserpine. J Pharmacol 138:351-357, 1962.
34. Crout JR. Effect of inhibiting both catechol-O-methyltransferase and monoamine oxidase on cardiovascular responses to norepinephrine. Proc Soc Exp Biol 108:482-484, 1961.
35. Hertting G, Axelrod J, Kopin IJ, Whitby LG. Lack of uptake of catecholamines after chronic denervation of sympathetic nerves. Nature 189:66-71, 1961.
36. Iversen LL. The uptake of catecholamines at high perfusion concentrations in the rat isolated heart: a novel catecholamine uptake process. Br J Pharmacol 25:18-23, 1965.
37. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91:35-62, 2001.
38. Eisenhofer G, Friberg P, Pacak K, et al. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin Sci (Lond) 88:533-542, 1995.
39. Eisenhofer G, Rundquist B, Aneman A, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 80:3009-3017, 1995.
40. Roth JA. Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev Physiol Biochem Pharmacol 120:1-29, 1992.
41. Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyl-transferase within tumors. J Clin Endocrinol Metab 83:2175-2185, 1998.
42. Ellingson T, Duddempudi S, Greenberg BD, Hooper D, Eisenhofer G. Determination of differential activities of soluble and membrane-bound catechol-O-methyltransferase in tissues and erythrocytes. J Chromatogr B Biomed Sci Appl 729:347-353, 1999.
43. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 305:800-811, 2003.
44. Cuche JL, Brochier P, Klioua N, et al. Conjugated catecholamines in human plasma: where are they coming from? J Lab Clin Med 116:681-686, 1990.
45. Rubin GL, Sharp S, Jones AL, Glatt H, Mills JA, Coughtrie MW. Design, production and characterization of antibodies discriminating between the phenol-and monoamine-sulphating forms of human phenol sulphotransferase. Xenobiotica 26:1113-1119, 1996.
46. Eisenhofer G, Aneman A, Friberg P, et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 82:3864-3871, 1997.
47. Goldstein DS, Swoboda KJ, Miles JM, et al. Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab 84:2523-2531, 1999.
48. Eisenhofer G, Coughtrie MW, Goldstein DS. Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol Suppl 26:S41-53, 1999.
49. LaBrosse EH, Comoy E, Bohuon C, Zucker JM, Schweisguth O. Catecholamine metabolism in neuroblastoma. J Natl Cancer Inst 57:633-638, 1976.
50. Sjoerdsma A, King WM, Leeper LC, Udenfriend S. Demonstration of the 3-methoxy analog of norepinephrine in man. Science 127:876, 1957.
51. Kopin IJ, Axelrod J. Presence of 3-methoxy-4-hydroxyphenylglycol and metanephrine in phaeochromocytoma tissue. Nature 185:788, 1960.
52. Sjoerdsma A, Leeper LC, Terry LL, Udenfriend S. Studies on the biogenesis and metabolism of norepinephrine in patients with pheochromocytoma. J Clin Invest 38:31-38, 1959.
53. Pisano JJ. A simple analysis of normetanephrine and metanephrine in urine. Clin Chem 5:406-414, 1960.
54. Crout JR, Pisano JJ, Sjoerdsma A. Urinary excretion of catecholamines and their metabolites in pheochromocytoma. Am Heart J 61:375-381, 1961.
55. Crout JR, Sjoerdsma A. Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Invest 43:94-102, 1964.
56. Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2:297-311, 2001.
57. DeQuattro V, Sullivan P, Foti A, et al. Central and regional normetadrenaline in evaluation of neurogenic aspects of hypertension: aid to diagnosis of phaeochromocytoma. Clin Sci (Lond) 59(Suppl 6):275s-277s, 1980.
58. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G. A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab 86:3641-3646, 2001.
59. Brown MJ. Simultaneous assay of noradrenaline and its deaminated metabolite, dihydroxyphenylglycol, in plasma: a simplified approach to the exclusion of phaeochromocytoma in patients with borderline elevation of plasma noradrenaline concentration. Eur J Clin Invest 14:67-72, 1984.
60. Peaston RT, Lai LC. Biochemical detection of phaeochromocytoma: should we still be measuring urinary HMMA? J Clin Pathol 46:734-737, 1993.
61. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141: 619-624, 1999.
62. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287:1427-1434, 2002.
63. Bravo EL, Tarazi RC, Gifford RW, Stewart BH. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 301:682-686, 1979.
64. van Heerden JA, Sheps SG, Hamberger B, Sheedy PF, 2nd, Poston JG, ReMine WH. Pheochromocytoma: current status and changing trends. Surgery 91:367-373, 1982.
65. Bravo EL, Gifford RW, Jr. Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 311:1298-1303, 1984.
66. Sinclair D, Shenkin A, Lorimer AR. Normal catecholamine production in a patient with a paroxysmally secreting phaeochromocytoma. Ann Clin Biochem 28 (Pt 4):417-419, 1991.
67. Stewart MF, Reed P, Weinkove C, Moriarty KJ, Ralston AJ. Biochemical diagnosis of phaeochromocytoma: two instructive case reports. J Clin Pathol 46:280-282, 1993.
68. Gerlo EA, Sevens C. Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. Clin Chem 40:250-256, 1994.
69. Shawar L, Svec F. Pheochromocytoma with elevated metanephrines as the only biochemical finding. J La State Med Soc 148:535-538, 1996.
70. Eisenhofer G. Free or total metanephrines for diagnosis of pheochromocytoma: what is the difference? Clin Chem 47:988-989, 2001.
71. Young WF, Jr. Pheochromocytoma: issues in diagnosis & treatment. Compr Ther 23:319-326, 1997.
72. Landsberg L, Young JB. Pheochromocytoma. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine, 15 ed. McGraw-Hill, New York, pp. 2105-2109, 2001.
73. Keiser HR. Pheochromocytoma and related tumors. In: DeGroot LJ, Jameson JL, eds. Endocrinology, 4 ed. Saunders, Philadelphia, pp 1862-1883, 2001.
74. Bravo EL. What is the best diagnostic approach when pheochromocytoma is suspected? Cleve Clin J Med 69:257-258, 2002.
75. Eisenhofer G, McCarty R, Pacak K, Russ H, Schomig E. Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn Schmiedebergs Arch Pharmacol 354:287-294, 1996.
76. Kobayashi K, Foti A, Dequattro V, Kolloch R, Miano L. A radioenzymatic assay for free and conjugated normetanephrine and octopamine excretion in man. Clin Chim Acta 107:163-173, 1980.
77. Mornex R, Peyrin L, Pagliari R, Cottet-Emard JM. Measurement of plasma methoxyamines for the diagnosis of pheochromocytoma. Horm Res 36:220-226, 1991.
78. Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 39:97-103, 1993.
79. Lenders JW, Keiser HR, Goldstein DS, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 123: 101-109, 1995.
80. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879, 1999.
81. Raber W, Raffesberg W, Bischof M, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160:2957-2963, 2000.
82. Sawka AM, Jaeschke R, Singh RJ, Young WF, Jr. A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553-558, 2003.
83. Eisenhofer G. Editorial: biochemical diagnosis of pheochromocytoma - is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab 88:550-552, 2003.
84. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: How to distinguish true-from false-positive test results. J Clin Endocrinol Metab 88:2656-2666, 2003.
85. Lagerstedt SA, O'Kane DJ, Singh RJ. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the analysis of free metanephrine and free normetanephrine in human plasma. Clin Chem 49 Suppl:A43, 2003.
86. Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162: 659-664, 1999.
87. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637-644, 2000.
88. Litchfield JW, Peart WS. Phaeochromocytoma with normal excretion of adrenaline and noradrenaline. Lancet 2:1283-1284, 1956.
89. Koch CA, Rodbard JS, Brouwers FM, Eisenhofer G, Pacak K. Hypotension in a woman with a metastatic dopamine-secreting carotid body tumor. Endocr Prac, in press, 2003.
90. Roden M, Raffesberg W, Raber W, et al. Quantification of unconjugated metanephrines in human plasma without interference by acetaminophen. Clin Chem 47: 1061-1067, 2001.
91. Taylor RL, Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem 48:533-539, 2002.
92. Raber W, Raffesberg W, Kmen E, et al. Pheochromocytoma with normal urinary and plasma catecholamines but elevated plasma free metanephrines in a patient with adrenal incidentaloma. Endocrinologist 10:65-68, 2000.